References
Creutzig U, van den Heuvel-Eibrink M, Gibson B, et al. diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187–205.
Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11:543–52.
Tsukimoto I, Tawa A, Horibe K, et al. Risk stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese child hood AML cooperative study group. J Clin Oncol. 2009;27:4007–13.
Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.
Yadav SP, Ramzan M, Lall M, Sachdeva A. Pediatric acute myeloid leukemia: final frontier for pediatric oncologists in the developing world. Pediatr Hematol Oncol. 2011;28:647–8.
Radhakrishnan V, Thampy C, Ganesan P, et al. Acute myeloid leukemia in children: experience from a tertiary center in India. Indian J Hematol Blood Transfus. 2016;32:257–61.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
None.
Source of Funding
None.
Rights and permissions
About this article
Cite this article
Seth, R., Pathak, N., Singh, A. et al. Pediatric Acute Myeloid Leukemia: Improved Survival Rates in India. Indian J Pediatr 84, 166–167 (2017). https://doi.org/10.1007/s12098-016-2234-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-016-2234-8